Literature DB >> 18318680

Stability of cefuroxime axetil oral suspension at different temperature storage conditions.

Alija Uzunović1, Edina Vranić.   

Abstract

Stability testing of an active substance or finished product provides information of the variation of drug substance or final product with time influenced by a variety of environmental factors such as temperature, humidity and light. Knowledge gained from stability studies enables understanding of the effects of the environment on the drugs. The aim of our study was to determine the stability of cefuroxime axetil oral suspension at different temperature storage conditions (stored at room /20 degrees C/ and refrigerated /5 degrees C/ conditions). Determination of cefuroxime (as cefuroxime axetil) was performed by dissolution testing. Fractions of the released cefuroxime axetil were compared using f2 value. After interpolating data for dissolution profiles at room and refrigerated conditions the following f2values were obtained: 62,56; 56,32 and 36,18 on 3rd, 6th and 10th day, respectively. These values indicate similarities in drug release from analyzed cefuroxime axetil oral suspension on 3rd, 6th day, and differences on 10th day. Based on our results, we may assume that cefuroxime axetil oral suspension preserves its stability for 10 days after reconstitution under room and refrigerated conditions. It is obvious, according to the f2 value obtained on the 10th day, that there is a difference between the released cefuroxime axetil from oral suspension at room (87,68%) and refrigerated (92,35%) conditions. Concentration changes can be caused by the mechanisms associated with drug release and hydrolytical decomposition of the sample and higher temperatures during longer period of storage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18318680      PMCID: PMC5724884          DOI: 10.17305/bjbms.2008.3005

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  5 in total

Review 1.  Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs).

Authors:  Andre S Raw; M Scott Furness; Devinder S Gill; Richard C Adams; Frank O Holcombe; Lawrence X Yu
Journal:  Adv Drug Deliv Rev       Date:  2004-02-23       Impact factor: 15.470

Review 2.  Cefuroxime axetil: an updated review of its use in the management of bacterial infections.

Authors:  L J Scott; D Ormrod; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Esters of cephalosporins. Part VI. Properties of the beta-form of 1-acetoxyethyl ester of cefuroxime.

Authors:  I Oszczapowicz; B Tejchman; A Zimniak; J Oszczapowicz
Journal:  Acta Pol Pharm       Date:  1998 May-Jun       Impact factor: 0.330

4.  [Antimicrobial activities of cefuroxime against recent clinical isolates].

Authors:  K Deguchi; N Yokota; M Koguchi; Y Suzuki; S Fukayama; R Ishihara; S Oda; S Tanaka; Y Nakane; T Fukumoto
Journal:  Jpn J Antibiot       Date:  1994-04

5.  Cefuroxime axetil.

Authors:  P Dellamonica
Journal:  Int J Antimicrob Agents       Date:  1994-03       Impact factor: 5.283

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.